Senthamizhchelvan Srinivasan1,2, John P Crandall3, Prateek Gajwani4, George Sgouros1, Esther Mena1, Martin A Lodge1, Richard L Wahl5,3. 1. Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Radiation Oncology, Memorial Health Care System, Chattanooga, Tennessee. 3. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; and. 4. Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland. 5. Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland rwahl@wustl.edu.
Abstract
Intravenous access is difficult in some patients referred for 18F-FDG PET imaging. Extravasation at the injection site and accumulation in central catheters can lead to limited tumor 18F-FDG uptake, erroneous quantitation, and significant image artifacts. In this study, we compared the human biodistribution and dosimetry for 18F-FDG after oral and intravenous administrations sequentially in the same subjects to ascertain the dosimetry and potential suitability of orally administered 18F-FDG as an alternative to intravenous administration. We also compared our detailed intravenous 18F-FDG dosimetry with older dosimetry data. Methods: Nine healthy volunteers (6 male and 3 female; aged 19-32 y) underwent PET/CT imaging after oral and intravenous administration of 18F-FDG. Identical preparation and imaging protocols (except administration route) were used for oral and intravenous studies. During each imaging session, 9 whole-body PET scans were obtained at 5, 10, 20, 30, 40, 50, 60, 120, and 240 min after 18F-FDG administration (370 ± 16 MBq). Source organ contours drawn using CT were overlaid onto registered PET images to extract time-activity curves. Time-integrated activity coefficients derived from time-activity curves were given as input to OLINDA/EXM for dose calculations. Results: Blood uptake after orally administered 18F-FDG peaked at 45-50 min after ingestion. The oral-to-intravenous ratios of 18F-FDG uptake for major organs at 45 min were 1.07 ± 0.24 for blood, 0.94 ± 0.39 for heart wall, 0.47 ± 0.12 for brain, 1.25 ± 0.18 for liver, and 0.84 ± 0.24 for kidneys. The highest organ-absorbed doses (μGy/MBq) after oral 18F-FDG administration were observed for urinary bladder (75.9 ± 17.2), stomach (48.4 ± 14.3), and brain (29.4 ± 5.1), and the effective dose was significantly higher (20%) than after intravenous administration (P = 0.002). Conclusion: 18F-FDG has excellent bioavailability after oral administration, but peak organ activities occur later than after intravenous injection. These data suggest PET at 2 h after oral 18F-FDG administration should yield images that are comparable in biodistribution to conventional clinical images acquired 1 h after injection. Oral 18F-FDG is a palatable alternative to intravenous 18F-FDG when venous access is problematic.
Intravenous access is difficult in some patients referred for 18F-FDG PET imaging. Extravasation at the injection site and accumulation in central catheters can lead to limited tumor 18F-FDG uptake, erroneous quantitation, and significant image artifacts. In this study, we compared the human biodistribution and dosimetry for 18F-FDG after oral and intravenous administrations sequentially in the same subjects to ascertain the dosimetry and potential suitability of orally administered 18F-FDG as an alternative to intravenous administration. We also compared our detailed intravenous 18F-FDG dosimetry with older dosimetry data. Methods: Nine healthy volunteers (6 male and 3 female; aged 19-32 y) underwent PET/CT imaging after oral and intravenous administration of 18F-FDG. Identical preparation and imaging protocols (except administration route) were used for oral and intravenous studies. During each imaging session, 9 whole-body PET scans were obtained at 5, 10, 20, 30, 40, 50, 60, 120, and 240 min after 18F-FDG administration (370 ± 16 MBq). Source organ contours drawn using CT were overlaid onto registered PET images to extract time-activity curves. Time-integrated activity coefficients derived from time-activity curves were given as input to OLINDA/EXM for dose calculations. Results: Blood uptake after orally administered 18F-FDG peaked at 45-50 min after ingestion. The oral-to-intravenous ratios of 18F-FDG uptake for major organs at 45 min were 1.07 ± 0.24 for blood, 0.94 ± 0.39 for heart wall, 0.47 ± 0.12 for brain, 1.25 ± 0.18 for liver, and 0.84 ± 0.24 for kidneys. The highest organ-absorbed doses (μGy/MBq) after oral 18F-FDG administration were observed for urinary bladder (75.9 ± 17.2), stomach (48.4 ± 14.3), and brain (29.4 ± 5.1), and the effective dose was significantly higher (20%) than after intravenous administration (P = 0.002). Conclusion: 18F-FDG has excellent bioavailability after oral administration, but peak organ activities occur later than after intravenous injection. These data suggest PET at 2 h after oral 18F-FDG administration should yield images that are comparable in biodistribution to conventional clinical images acquired 1 h after injection. Oral 18F-FDG is a palatable alternative to intravenous 18F-FDG when venous access is problematic.
Authors: M Masud; K Yamaguchi; H Rikimaru; M Tashiro; K Ozaki; S Watanuki; M Miyake; T Ido; M Itoh Journal: Ann Nucl Med Date: 2001-02 Impact factor: 2.668
Authors: T Shingaki; T Takashima; Y Wada; M Tanaka; M Kataoka; A Ishii; Y Shigihara; Y Sugiyama; S Yamashita; Y Watanabe Journal: Clin Pharmacol Ther Date: 2012-02-29 Impact factor: 6.875
Authors: Se Jong Oh; Namhun Lee; Kyung Rok Nam; Kyung Jun Kang; Sang Jin Han; Kyo Chul Lee; Yong Jin Lee; Jae Yong Choi Journal: Front Neurosci Date: 2022-08-05 Impact factor: 5.152
Authors: Isaac M Jackson; So Jeong Lee; Alexandra R Sowa; Melissa E Rodnick; Laura Bruton; Mara Clark; Sean Preshlock; Jill Rothley; Virginia E Rogers; Leslie E Botti; Bradford D Henderson; Brian G Hockley; Jovany Torres; David M Raffel; Allen F Brooks; Kirk A Frey; Michael R Kilbourn; Robert A Koeppe; Xia Shao; Peter J H Scott Journal: EJNMMI Radiopharm Chem Date: 2020-11-11